2nd Jun 2016 09:16
LONDON (Alliance News) - Gene and cell therapy company Oxford Biomedica PLC on Thursday said it has signed a research and development collaboration deal with Green Cross LabCell.
Green Cross LabCell is a subsidiary of South Korean biopharmaceutical firm Green Cross Holdings.
Under the agreement, the pair will focus on identifying and developing gene-modified natural killer cell-based therapeutics for treatment of life-threatening diseases, including cancer.
The two will share the costs of the collaboration equally.
"We are very excited to form a key partnership with Green Cross LabCell, who have the industry-leading production platform for NK cell therapeutics for cancer," said John Dawson, Oxford Biomedica's chief executive.
Oxford Biomedica shares were up 6.3% to 5.66 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica